| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Outline of Final Research Achievements |
Dehydroxymethylepoxyquinomicin (DHMEQ) is a novel nuclear factor (NF)-kB inhibitor. We investigated whether DHMEQ can modulate the proinflammatory cytokine induced expression of intracellular adhesion molecule (ICAM)-1 and chemokines in a human retinal pigment epithelial (RPE) cell line (ARPE-19). In addition, we investigated whether intravitreal injection of DHMEQ was effective for suppression of experimental autoimmune uveoretinitis (EAU). DHMEQ effectively down-regulated the expression of ICAM-1 in TNF-alpha stimulated ARPE-19 cells. Furthermore, DHMEQ suppressed the production of both IL-8 and MCP-1. However, there was no significant difference in EAU clinical score between control eyes and DHMEQ-treated eyes in EAU-induced rats. These results suggest that DHMEQ may play a role in reducing ICAM-1 and chemokine mediated inflammatory disorders in the eye, however further study is warranted for clinical application of DHMEQ for autoimmune uveitis.
|
